Corrigendum to: Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated (Diabetes Metab Syndr Obes, (2014), 7, (15-24), 10.2147/DMSO.S38753);Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated

Diabetes, Metabolic Syndrome and Obesity

Volumn 7, Issue , 2014, Pages 15-24

  Irons, Brian K ^a   Minze, Molly G ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Hyperglycemia; Metformin; Monotherapy; Pharmacotherapy; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ALOGLIPTIN; BROMOCRIPTINE; CANAGLIFLOZIN; COLESEVELAM; DAPAGLIFLOZIN; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; VOGLIBOSE;

ADD ON THERAPY; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 84892698797     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S154662     Document Type: Erratum

References (72)

1. International Diabetes Federation. Global guideline for type 2 diabetes. Available from: http://www.idf.org/global-guideline-type-2-diabetes-2012. Accessed September 5, 2013.
2. National Institute for Health and Clinical Excellence. Type 2 diabetes: The management of type 2 diabetes (NICE clinical guideline 87). Available from: http://www.nice.org.uk/guidance/CG87. Accessed August 15, 2013.
3. Inzucchi SE, Bergenstal RM, Buse JB, etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35:1364-1379.
4. Garber AJ, Abrahamson MJ, Barzilay JI, etal. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract. 2013;19 Suppl 2:1-48.
5. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:385-411.
6. Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes. Diabetes. 2004;53 Suppl 3:S151-S155.
7. Carroll MF, Izard A, Riboni K, Burge MR, Schade DS. Control of postprandial hyperglycemia. Diabetes Care. 2002;25:2147-2152.
8. Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
9. Kahn S, Haffner S, Heise M, etal. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355: 2427-2443.
10. Turner RC, Holman RR, Cull CA, etal; UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352: 837-853.
11. Rosenstock J, Hassman DR, Madder RD, etal. Repaglinide versus nateglinide monotherapy. Diabetes Care. 2004;27:1265-1270.
12. Gallwitz B. Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs. 2011;71:1675-1688.
13. Moretto TJ, Milton DR, Ridge TD, etal. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448-1460.
14. Russell-Jones D, Cuddihy RM, Hanefeld M, etal. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4). Diabetes Care. 2012;35:252-258.
15. Blevins T, Pullman J, Malloy J, etal. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301-1310.
16. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13: 348-356.
17. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin. Diabetes Care. 2010;33: 2349-2354.
18. Dore DD, Seeger JD, Chan AK. Use of claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25:1019-1027.
19. Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care. 2013;36 Suppl 2:S245-S252.
20. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013;41:72-84.
21. Stenlöf K, Cefalu WT, Kim KA, etal. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372-383.
22. Inagaki N, Kondo K, Yoshinari T, Maruyama N, Sustuta Y, Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15:1136-1145.
23. Pilodori D, Sha S, Mudaliar S, etal. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion. Diabetes Care. 2013;36: 2154-2161.
24. Nisly SA, Kolanczyk DM, Walton AM. Canagliflozin, a new sodium-glucose cotransporter 2inhibitor, in the treatment of diabetes. Am J Health Syst Pharm. 2013;70:311-319.
25. Misra M. SGLT2inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharm Pharmacol. 2012;65: 317-327.
26. Burki T. FDA rejects novel diabetes drug over safety fears. Lancet. 2012;379:507.
27. Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy. 2013;33:984-999.
28. Irons BK, Weis JM, Stapleton MR, Edwards KL. An update in incretin-based therapy: a focus on dipeptidyl peptidase-4inhibitors. Curr Diabetes Rev. 2012;8:169-182.
29. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369.
30. Esposito K, Cozzolino D, Bellastella G, etal. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2011;13:594-603.
31. Scirica B, Bhatt D, Braunwald E, etal. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.
32. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes. Diabetes Care. 2009;32:834-838.
33. Engel SS, Williams-Herman DE, Golm GT, etal. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract. 2010;64:984-990.
34. Chaisson JL, Josse RG, Hunt JA, etal. The efficacy of acarbose in the treatment of patients with non-insulin dependent diabetes mellitus. Ann Intern Med. 1994;121:928-935.
35. Johnston PS, Lebovitz HE, Conniff RF, Simonson DC, Raskin P, Munera CL. Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab. 1998;183: 1515-1522.
36. Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000;59:521-549.
37. Buse J, Hart K, Minasi LA. The PROTECT study: final results in a large multicenter postmarketing study in patients with type 2 diabetes. Clin Ther. 1998;20:257-269.
38. Takami K, Takeda N, Nakashima K, etal. Effects of dietary treatment alone diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2002;25:658-662.
39. Iwamoto Y, Tajima N, Kadowaki T, etal. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab. 2010;12:613-622.
40. Handelsman Y. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care. 2011;34 Suppl 2:S244-S250.
41. Smushkin G, Sathananthan M, Piccinini F, etal. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes. 2013;62:1094-1101.
42. Schwartz SL, Lai YL, Xu J, etal. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord. 2010;8:179-187.
43. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31:1479-1484.
44. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168:1531-1540.
45. Rigby S, Handelsman Y, Lai Y, Abby S, Tao B, Jones MR. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract. 2010;16:53-63.
46. Goldfine AB, Fonseca VA, Jones MR, Wang AC, Ford DM, Truitt KE. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res. 2010;42:23-3-.
47. Bays HE. Long-term (52-78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients. Diabetes Metab Syndr Obes. 2012;5:125-134.
48. Holt RI, Barnett AH, Bailey CJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab. 2010;12:1048-1057.
49. DeFronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34:789-794.
50. Pijil H, Ohashi S, Matsuda M, etal. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23:1154-1161.
51. Scranton R, Cincotta A. Bromocriptine-unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2010;11:269-279.
52. Kerr JL, Timpe EM, Petkewicz KA. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Ann Pharmacother. 2010;44:1777-1785.
53. Gaziano JM, Cincotta AH, O'Connor CM, etal. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33: 1503-1508.
54. Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc. 2012;1:e002279.
55. Raccah D. Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus. Diabetes Obes Metab. 2008;10 Suppl 2:76-82.
56. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-259.
57. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27: 1028-1032.
58. Li Y, Xu W, Liao Z, etal. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004;27:2597-2602.
59. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008;31:1927-1932.
60. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013;98:668-677.
61. Schernthaner G, Currie CJ, Schernthaner GH. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care. 2013;36 Suppl 2:S155-S161.
62. Pavo I, Jermendy G, Varkonyi TT, etal. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:1637-1645.
63. Perez-Monteverde A, Seck T, Xu L, etal. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs pioglitazone in drug-naïve patients with type 2 diabetes. Int J Clin Pract. 2011;65:930-938.
64. Wainstein J, Katz L, Engel SS, etal. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14: 409-418.
65. Tan MH, Baksi A, Krahulec B, etal. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. 2005;28:544-550.
66. Dormandy JA, Charbonnel B, Eckland DJ, etal. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study. Lancet. 2005;366:1279-1289.
67. Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009;169:1395-1402.
68. Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med. 2012;172:1005-1011.
69. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953-1962.
70. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36 Suppl 2:S127-S138.
71. Glucophage (metformin hydrochloride tablets) FDA-approved label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf. Accessed September 25, 2013.
72. United Kingdom Medicines and Healthcare Products Regulatory Agency. Metformin Summary of Product Characteristics. Available from: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1376454233492.pdf. Accessed September 25, 2013.